Zydus Bags Us Fda Final Approval To Market Dapagliflozin Tablets
Zydus Cadila Announced That It Has Received Final Approval From The Us Food And Drug Administration (Fda) To Market Type 2 Diabetes Drug Dapagliflozin In The Country.The Approval Is For Dapagliflozin Tablets In The Strengths Of 5 Mg And 10 Mg. The Drug Is Used With A Proper Diet And Exercise Program To Control High Blood Sugar In People With Type 2 Diabetes.It Also Lowers The Risk Of Heart Failure In Adults With Type 2 Diabetes With Heart Disease. It Is Also Used To Lower The Risk Of Further Worsening Of Kidney Disease, End-Stage Kidney Disease (Eskd), Death Due To Cardiovascular Disease, And Hospitalization For Heart Failure In Adults With Chronic Kidney Disease. The Medicine Works By Increasing The Removal Of Sugar By Kidneys.The Drug Will Be Manufactured At The Group
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
